Myositis ossificans in children: a review.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] 14. Expert Opin Pharmacother. 2024 Nov;25(16):2225-2234. doi: 10.1080/14656566.2024.2422548. Epub 2024 Oct 28. Current and emerging treatment modalities for fibrodysplasia ossificans progressiva. Gençel D(1), Erbil NN(1), Demiryürek Ş(2), Demiryürek AT(3). Author information: (1)Faculty of Medicine, Gaziantep University, Gaziantep, Turkey. (2)Department of Physiology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey. (3)Department of Medical Pharmacology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey. INTRODUCTION: Heterotopic ossification (HO), acquired or hereditary, is a diverse pathological condition defined by the production of extraskeletal bone in muscles, soft tissues, and connective tissues. Acquired HO is relatively prevalent and develops mostly in response to trauma, although its etiology is unknown. Genetic forms provide insight into the pathobiological mechanisms of this disorder. Fibrodysplasia ossificans progressiva (FOP) is a rare hereditary form of HO that can have a significant impact on affected individuals. FOP steadily weakens affected subjects and increases their risk of death. AREAS COVERED: The U.S. Food and Drug Administration has recently approved the retinoid palovarotene as the first compound to treat heterotopic ossification in patients with FOP. This review provides a comprehensive overview of current and potential future pharmacotherapeutic options and their modes of action. The online databases PubMed, Cochrane Library, Web of Science, and ClinicalTrials.gov were searched using the terms 'heterotopic ossification' and 'fibrodysplasia ossificans progressiva' or synonyms, with a special focus over the last 5 years of publications. EXPERT OPINION: Approval of palovarotene, as the first retinoid indicated for reduction in the volume of new HO, may revolutionize the therapeutic landscape. However, long-term safety and efficacy data for palovarotene are currently lacking. DOI: 10.1080/14656566.2024.2422548